Novartis initiates post-approval study of secukinumab for hidradenitis suppurativa in China
Novartis is conducting a post-approval study to assess the efficacy and safety of secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa, comparing two dosing regimens.